|
Admelog
Sept 1, 2017 14:57:01 GMT -5
via mobile
Post by uvula on Sept 1, 2017 14:57:01 GMT -5
What is admelog and how is it different?
|
|
|
Post by peppy on Sept 1, 2017 15:19:10 GMT -5
|
|
|
Admelog
Sept 1, 2017 17:20:07 GMT -5
Post by agedhippie on Sept 1, 2017 17:20:07 GMT -5
It's their Humalog biosimilar.
|
|
|
Admelog
Sept 2, 2017 2:04:05 GMT -5
Post by babaoriley on Sept 2, 2017 2:04:05 GMT -5
Sanofi is looking to hire MNKD's sales force en masse to market their new rapid insulin product, yup every last one of those sales wizards. Apparently, they are blown away by the Afrezza's sales to date. Seems strange to me, and I don't believe it, but one hears just about everything if one listens well enough. As to you direct question, uvula, how is it different? Well, they will likely sell a whole bunch more of it than they did Afrezza, that's the big difference to me.
|
|
|
Admelog
Sept 2, 2017 2:17:35 GMT -5
Post by straightly on Sept 2, 2017 2:17:35 GMT -5
Sanofi is looking to hire MNKD's sales force en masse to market their new rapid insulin product, yup every last one of those sales wizards. Apparently, they are blown away by the Afrezza's sales to date. Seems strange to me, and I don't believe it, but one hears just about everything if one listens well enough. As to you direct question, uvula, how is it different? Well, they will likely sell a whole bunch more of it than they did Afrezza, that's the big difference to me. Sad but true. It is not easy to be an underdog. It is very hard to be an underdog fighting for survival. At current price level, even better if it goes down to $1.54, we will be awarded bountifully if MNKD survives. Have to stop here before I convince myself to buy even more.
|
|
|
Post by mango on Sept 2, 2017 2:27:56 GMT -5
Sanofi is looking to hire MNKD's sales force en masse to market their new rapid insulin product, yup every last one of those sales wizards. Apparently, they are blown away by the Afrezza's sales to date. Seems strange to me, and I don't believe it, but one hears just about everything if one listens well enough. As to you direct question, uvula, how is it different? Well, they will likely sell a whole bunch more of it than they did Afrezza, that's the big difference to me. Sad but true. It is not easy to be an underdog. It is very hard to be an underdog fighting for survival. At current price level, even better if it goes down to $1.54, we will be awarded bountifully if MNKD survives. Have to stop here before I convince myself to buy even more. MannKind has been an underdog the moment Al Mann created the company. It has survived from the very things that do not exist among the affairs of corruption.
|
|
|
Post by sayhey24 on Sept 2, 2017 6:43:31 GMT -5
The question I ask is what is BPs next move? Sanofi is now trying to get a piece of the Humalog market. Lilly has nothing new. Novo's Fiasp is turning out to be a mess and as they said in Forbe's after Tresiba they can't do any better in the basal area. As we saw at ADA 2017 they don't have many new offering in the pipeline.
afrezza clearly obsoletes all the RAAs - Ademlog, Humalog, Novalog and the rest. If it becomes a price war, MNKD's manufacturing and overhead costs are significantly below all of BP. From a manufacturing perspective it is all automated and takes 6 people a shift to man the process and you can fill a lot of cartridges in an 8 hour shift.
One thing we do know is afrezza is too damn expensive. They need to get it in the "Correction" packages and let it sell for $20 OTC in those states which view it as "human insulin" and require no prescription. They also need to get the price down to $99 a box and sell direct over amazon. I wonder what Dachis has been doing to make the Amazon talk real?
|
|
|
Admelog
Sept 2, 2017 7:39:32 GMT -5
Post by diamonddave on Sept 2, 2017 7:39:32 GMT -5
For the past few months Lilly has been running a tv commercial for participants in trial for an ultra rapid mealtime insulin here in south florida. Not sure what that is all about.
|
|
|
Post by lennymnkd on Sept 2, 2017 8:16:26 GMT -5
The question I ask is what is BPs next move? Sanofi is now trying to get a piece of the Humalog market. Lilly has nothing new. Novo's Fiasp is turning out to be a mess and as they said in Forbe's after Tresiba they can't do any better in the basal area. As we saw at ADA 2017 they don't have many new offering in the pipeline. afrezza clearly obsoletes all the RAAs - Ademlog, Humalog, Novalog and the rest. If it becomes a price war, MNKD's manufacturing and overhead costs are significantly below all of BP. From a manufacturing perspective it is all automated and takes 6 people a shift to man the process and you can fill a lot of cartridges in an 8 hour shift. One thing we do know is afrezza is too damn expensive. They need to get it in the "Correction" packages and let it sell for $20 OTC in those states which view it as "human insulin" and require no prescription. They also need to get the price down to $99 a box and sell direct over amazon. I wonder what Dachis has been doing to make the Amazon talk real? Imagine that scenario on a global ievel , giddy up !!!
|
|
|
Admelog
Sept 2, 2017 9:20:21 GMT -5
Post by agedhippie on Sept 2, 2017 9:20:21 GMT -5
For the past few months Lilly has been running a tv commercial for participants in trial for an ultra rapid mealtime insulin here in south florida. Not sure what that is all about. Good catch. I am not sure if this is what is about but there are some trials registered for LY900014 (PRONTO-T1D/T2D) which looks like their new insulin. Florida doesn't appear as a trial location but that may be updated. Interestingly they have an arm with insulin taken 20 minutes after the start of the meal. Scheduled for primary completion 9/2018, completed study results 9/2019. This is about chasing the AP market, they need fast insulins for the pump. It does make the creation of the ultra rapid class more likely as well.
|
|
|
Admelog
Sept 2, 2017 9:43:06 GMT -5
Post by peppy on Sept 2, 2017 9:43:06 GMT -5
For the past few months Lilly has been running a tv commercial for participants in trial for an ultra rapid mealtime insulin here in south florida. Not sure what that is all about. Good catch. I am not sure if this is what is about but there are some trials registered for LY900014 (PRONTO-T1D/T2D) which looks like their new insulin. Florida doesn't appear as a trial location but that may be updated. Interestingly they have an arm with insulin taken 20 minutes after the start of the meal. Scheduled for primary completion 9/2018, completed study results 9/2019. This is about chasing the AP market, they need fast insulins for the pump. It does make the creation of the ultra rapid class more likely as well. the problem with the pump is they are subq.
what rapid actings are best IV aged? www.smiths-medical.com/products/vascular-access/implantable-ports/portacath-implantable-venous-access-systems plug the pump in that and change the settings.
|
|
|
Post by agedhippie on Sept 2, 2017 10:39:34 GMT -5
Good catch. I am not sure if this is what is about but there are some trials registered for LY900014 (PRONTO-T1D/T2D) which looks like their new insulin. Florida doesn't appear as a trial location but that may be updated. Interestingly they have an arm with insulin taken 20 minutes after the start of the meal. Scheduled for primary completion 9/2018, completed study results 9/2019. This is about chasing the AP market, they need fast insulins for the pump. It does make the creation of the ultra rapid class more likely as well. the problem with the pump is they are subq.
what rapid actings are best IV aged? www.smiths-medical.com/products/vascular-access/implantable-ports/portacath-implantable-venous-access-systems plug the pump in that and change the settings.
That's the way to do it! You could go the whole 9 yards though and implant the pump ( www.healthline.com/diabetesmine/implantable-insulin-pumps). I know someone who has one of these. Interestingly the pump was made by MiniMed and you have to wonder how much it influenced Al Mann. The insulin passes almost directly into the blood stream as it drips into the peritoneal cavity. When he made it I can imagine Al thinking, "Well that works, but I need a better route".
|
|
|
Admelog
Sept 2, 2017 11:12:20 GMT -5
Post by peppy on Sept 2, 2017 11:12:20 GMT -5
That's the way to do it! You could go the whole 9 yards though and implant the pump ( www.healthline.com/diabetesmine/implantable-insulin-pumps). I know someone who has one of these. Interestingly the pump was made by MiniMed and you have to wonder how much it influenced Al Mann. The insulin passes almost directly into the blood stream as it drips into the peritoneal cavity. When he made it I can imagine Al thinking, "Well that works, but I need a better route". what insulin are they using in slow drip pump into the peritoneal? (the peritoneal reminds me of dialysis. )
|
|
|
Post by mango on Sept 2, 2017 13:23:55 GMT -5
The question I ask is what is BPs next move? Sanofi is now trying to get a piece of the Humalog market. Lilly has nothing new. Novo's Fiasp is turning out to be a mess and as they said in Forbe's after Tresiba they can't do any better in the basal area. As we saw at ADA 2017 they don't have many new offering in the pipeline. afrezza clearly obsoletes all the RAAs - Ademlog, Humalog, Novalog and the rest. If it becomes a price war, MNKD's manufacturing and overhead costs are significantly below all of BP. From a manufacturing perspective it is all automated and takes 6 people a shift to man the process and you can fill a lot of cartridges in an 8 hour shift. One thing we do know is afrezza is too damn expensive. They need to get it in the "Correction" packages and let it sell for $20 OTC in those states which view it as "human insulin" and require no prescription. They also need to get the price down to $99 a box and sell direct over amazon. I wonder what Dachis has been doing to make the Amazon talk real? Regarding Sanofi...the Army (BARDA) "paused" their collaboration with Sanofi for the research and development of a Zika virus vaccine, essentially—indefinitely. Researchers are slow to understand why certain vaccines suck, notably the intranasal live attenuated flu vaccine, FluMist. It's ineffective and quite frankly a crappy vaccine. No excuse for trying to pump children full of questionable formulations developed by a company that cannot even maintain CGMP (they have received an FDA Warning Letter for botched manufacturing of FluMist). Children need safe and effective vaccines, not crap vaccines that don't work (and manufactured by a company that doesn't care). So far I know of only one company capable of developing and manufacturing safe therapeutics. And I don't see a point in a middle man (Amazon) as long as MannKind is the one that manufactures the product.
|
|
|
Post by rockstarrick on Sept 2, 2017 15:01:35 GMT -5
The question I ask is what is BPs next move? Sanofi is now trying to get a piece of the Humalog market. Lilly has nothing new. Novo's Fiasp is turning out to be a mess and as they said in Forbe's after Tresiba they can't do any better in the basal area. As we saw at ADA 2017 they don't have many new offering in the pipeline. afrezza clearly obsoletes all the RAAs - Ademlog, Humalog, Novalog and the rest. If it becomes a price war, MNKD's manufacturing and overhead costs are significantly below all of BP. From a manufacturing perspective it is all automated and takes 6 people a shift to man the process and you can fill a lot of cartridges in an 8 hour shift. One thing we do know is afrezza is too damn expensive. They need to get it in the "Correction" packages and let it sell for $20 OTC in those states which view it as "human insulin" and require no prescription. They also need to get the price down to $99 a box and sell direct over amazon. I wonder what Dachis has been doing to make the Amazon talk real? Regarding Sanofi...the Army (BARDA) "paused" their collaboration with Sanofi for the research and development of a Zika virus vaccine, essentially—indefinitely. Researchers are slow to understand why certain vaccines suck, notably the intranasal live attenuated flu vaccine, FluMist. It's ineffective and quite frankly a crappy vaccine. No excuse for trying to pump children full of questionable formulations developed by a company that cannot even maintain CGMP (they have received an FDA Warning Letter for botched manufacturing of FluMist). Children need safe and effective vaccines, not crap vaccines that don't work (and manufactured by a company that doesn't care). So far I know of only one company capable of developing and manufacturing safe therapeutics. And I don't see a point in a middle man (Amazon) as long as MannKind is the one that manufactures the product. Sanofi would come out of a "wet dream" dry as a bone 🍖 😂😂😂😂😂😂😂😂 How they botched owning 65% of Afrezza for next to nothing literally says it all. That has to be the biggest f-up in the history of Pharma. I hope they sink to the bottom. 🇺🇸
|
|